Abstract
Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the "autocrine" production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.
| Original language | English |
|---|---|
| Pages (from-to) | 205-209 |
| Number of pages | 5 |
| Journal | Leukemia and Lymphoma |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 1 1993 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
- Cancer Research
Cite this
The role of interleukin-4 in the negative regulation of leukemia cell growth. / Akashi, Koichi.
In: Leukemia and Lymphoma, Vol. 9, No. 3, 01.01.1993, p. 205-209.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of interleukin-4 in the negative regulation of leukemia cell growth
AU - Akashi, Koichi
PY - 1993/1/1
Y1 - 1993/1/1
N2 - Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the "autocrine" production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.
AB - Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the "autocrine" production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0027298317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027298317&partnerID=8YFLogxK
U2 - 10.3109/10428199309147371
DO - 10.3109/10428199309147371
M3 - Article
C2 - 7682464
AN - SCOPUS:0027298317
VL - 9
SP - 205
EP - 209
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3
ER -